Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx (Nasdaq: CDNA) introduced AlloSeq Nano, a nanopore long‑read HLA and ABO genotyping assay delivering high‑resolution results in under three hours and about 45 minutes hands‑on for eleven HLA loci plus ABO.
The company is showcasing AlloSeq Nano at EFI 2026 on April 23 and announced a definitive agreement to divest its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026.
CareDx (Nasdaq: CDNA) agreed to sell its Lab Products business to EuroBio Scientific for $170 million, aiming to sharpen focus on Precision Medicine Testing Services and Patient and Digital Solutions.
Key terms include a perpetual North America distribution right for post-transplant IVD tests including AlloSeq cfDNA, expected close by end of Q3 2026 pending Swedish regulatory review, and at least six months of transition services. Preliminary Q1 2026 results: $118M revenue (+39% YoY), Testing Services revenue $91M (+48% YoY), testing volume ~54,900 (+17% YoY), Patient and Digital $16M (+33%), Lab Products $10M (-4%), and cash ~$198M as of March 31, 2026.
CareDx (Nasdaq: CDNA) will report first quarter 2026 financial results after market close on April 28, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET that day.
A live and archived webcast will be available on the Events & Presentations section of CareDx's Investor Relations website; telephone participants must register to receive a dial-in number and PIN.
CareDx (Nasdaq: CDNA) launched VANTx, an AI‑powered, cloud‑native clinical data and analytics platform announced March 5, 2026. VANTx ingests real‑time, de‑identified molecular and clinical data, runs on Databricks with the Llama 3 foundational model, and supports cohort analysis, research, and real‑world evidence generation.
Available now via medical affairs consultation, CareDx plans self‑service, permissioned clinician access later in 2026.
CareDx (Nasdaq: CDNA) awarded inducement restricted stock unit grants to 35 new employees totaling 82,137 RSUs on February 24, 2026, under its 2016 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years: 25% on the first anniversary of each employee's vesting commencement date and then 1/16th quarterly thereafter, subject to continued service.
CareDx (Nasdaq: CDNA) announced that Keith Kennedy, currently Chief Operating Officer, will also assume the role of Chief Financial Officer effective February 26, 2026.
Kennedy brings over 20 years of healthcare leadership, seven years of public-company CFO experience, prior CFO roles including PharmaLogic (Apr 2022–Sep 2024), and credentialing as a CFA and CPA. Nathan Smith will step down as CFO, as announced on the company’s quarterly earnings call.
Summary not available.
CareDx (Nasdaq: CDNA) will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026.
The company is expected to present its recent developments in transplant precision medicine and engage with investors and analysts during the conference.
CareDx (Nasdaq: CDNA) announced clinical validation of AlloHeme, an AI‑powered, NGS blood test to surveil relapse in AML and MDS after allogeneic HCT.
The ACROBAT study (198 subjects, 40 relapse events) showed 85% sensitivity, 92% specificity, 95% NPV, 79% PPV, AUC 0.89, and a median 41‑day lead time. CareDx expects CLIA readiness in 2026, commercial launch in 2027, and payer coverage in 2028.
CareDx (Nasdaq: CDNA) will report fourth quarter and full year 2025 financial results after market close on Tuesday, February 24, 2026. A webcast and conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET.
Live and archived webcast access is available on the Events & Presentations section of CareDx's Investor Relations website, and telephone participation requires registration to receive a dial-in number and unique PIN.